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ABSTRACT. Efficacy and safety of intravenous and intra-
muscular vitamin K were compared prospectively in patients
receiving total parenteral nutrition. Sixty patients randomly
received either a 1-mg daily iv injection (iv group) or a 10-mg
weekly injection group (im group). Efficacy was determined by
the prolongation of twice-weekly prothrombin (PT) and acti-
vated partial thromboplastin (APTT) times. The prolongation
of both was not significantly different between the im and iv
groups. The percent of PTs outside the normal range was not
different for the two groups, although the iv group had more
APTT values outside the range than did the im group (p =
0.002). The number of adverse reactions reported in the iv (5)
and im (4) groups was also similar. Reactions were minor, not
reproducible, and all patients recovered without sequelae. PT
results from the iv and im groups were combined and compared
to values from 28 patients in an earlier study who did not
receive vitamin K. PTs in the no-vitamin K group were signif-
icantly prolonged over the vitamin K group (p = 0.0004). The
results confirm that regular addition of vitamin K to TPN
regimens decreases the incidence of elevated PTs. When ad-
ministered appropriately, iv and im administration of vitamin
K appear to be equally safe and effective in maintaining normal
PTs and APTTs. (Journal of Parenteral and Enteral Nutrition
12:174-177, 1988)
Total parenteral nutrition (TPN) has been shown to
be a safe and effective method of providing nutrition for
patients unable to tolerate an adequate oral diet.I-3 TPN
solutions commonly contain glucose, amino-acid mix-
tures, electrolytes, fat emulsions, trace elements, and
vitamins including vitamin K.’ Vitamin K is indicated
for patients with coagulation disorders, malabsorption
syndromes, and for those who are unable to maintain an
adequate oral intake.’ Vitamin K is necessary for the
liver synthesis of clotting factors II, VII, IX, and X which
are essential for maintaining normal hemostasis. Mini-
mum adult daily requirements range from 0.03-1.5 jug/
kg body weight.’
The association of vitamin K deficiency with bleeding
abnormalities has been well documented.’-1° The oral
preparation requires the presence of bile salts in the
intestine for proper absorption. Because absorption is
often unpredictable, the intramuscular or subcutaneous
preparation has generally been preferred. Alternatively,
vitamin K can be administered intravenously to improve
prothrombin response rapidly in severe hemorrhagic
states associated with hypoprothrombinemia, and to pa-
tients who fail to respond to other routes of administra-
tiOn.l1-13
A previous study at our institution showed that pa-
tients who received TPN solutions for varying lengths
of time and did not receive vitamin K demonstrated a
high incidence of prolonged prothrombin times.&dquo; Review
of the literature for vitamin K requirements and admin-
istration guidelines revealed conflicting recommenda-
tions. Merck Sharp and Dohme, which manufacturers
an injectable form of vitamin K, cautions that deaths
have occurred after rapid intravenous administration and
further states that transient flushing, taste disturbances,
dizziness, rapid and weak pulses, profuse sweating, hy-
potension, dyspnea, and cyanosis have been reported
after vitamin K injection.’ Whether these reactions were
due to vitamin K or the vehicles used in commercial
preparations is unclear. Their cautionary statements
have been justified by other recent clinical evidence of
adverse reactions following rapid intravenous injection
of vitamin K. There have been four case reports of
patients receiving vitamin K 5- to 10-mg iv over short
periods of time (three patients, 2-10 min, one patient,
45 min) who subsequently experienced major adverse
reactions. There were two episodes of cardiovascular
collapse, one of severe hypotension, and one of general-
ized body tremors.15-18 Six (0.5%) adverse reactions were
documented in the Boston Collaborative Drug Surveil-
lance Program (1966-1975) in which 1238 patients re-
ceived vitamin K. Two patients developed erythematous
rashes, two injection-site complications, one a fever, and
one a grand mal seizure.19
In spite of these cautions, vitamin K can safely be
given intravenously particularly when it is not adminis-
tered rapidly. Pridmore et al2’ described the uncompli-
cated regular intravenous administration of 5 mg of
vitamin K to 15 patients during pregnancy. Frick et a16
noted the safe use of small amounts of vitamin K in 10
patients on starvation diets receiving antibiotic therapy.
In addition, hospitals are beginning to add vitamin K to
TPN solutions intended for intravenous administration.
In light of these reports, questions remain concerning
a
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the safety, the optimal route of administration, and the
daily requirement of vitamin K. The specific aims of this
study were to: (1). determine if a 1-mg intravenous dose
of vitamin K daily is as effective as a weekly intramus-
cular 10-mg dose in maintaining normal prothrombin
and activated partial thromboplastin times. (2). deter-
mine if there is a difference in the incidence of adverse
reactions among TPN patients receiving intravenous or
intramuscular vitamin K. (3). confirm that regular ad-
dition of vitamin K to TPN regimens results in a lower
incidence of abnormal prothrombin times.
METHODS
Patient Selection
From April 1985 to December 1985, 60 patients receiv-
ing total parenteral nutrition entered our prospective
study. Patients received either 1 mg of vitamin K per
day in their TPN solutions (iv group) or a 10-mg weekly
intramuscular injection of vitamin K (im group). The
vitamin K used in this study (Aquamephyton) was ob-
tained from Merck Sharp and Dohme. Exclusion criteria
were known hypersensitivity to vitamin K, history of a
bleeding disorder, concurrent oral diet, administration of
warfarin, vitamin K (other than protocol), or blood prod-
ucts 1 week prior to or during TPN; and receipt of TPN
for less than 5 days.
In 1981, 28 patients at our institution who received
TPN but did not receive vitamin K were studied by the
TPN team.14 Data from the 28 patients were compared
with that from the 60 patients (iv + im groups) in the
present study to evaluate the effect of regular vitamin K
administration.
Study Design
Sixty patients were randomized into the intravenous
or intramuscular group using the last digit of their social
security number. Thirty-four patients received intrave-
nous vitamin K and 26 received intramuscular. Prior to
initiation of TPN therapy, the TPN team pharmacist
reviewed the patients medical record to identify any
medications or diseases that might influence vitamin K
response. The primary physician was notified concerning
the proposed route of administration or ineligibility for
the study. The study was carefully explained to patients
and written consent was obtained. Patients who were
ineligible or declined to participate received the standard
institutional TPN solutions.
To determine the effectiveness of the vitamin K ad-
ministration in the iv and im groups, prothrombin times
(PT) and activated partial thromboplastin times (APTT)
were taken twice a week. The mean PT reference value
at our institution is 10.7 sec (range 8.4-13 sec). Our mean
APTT reference value is 26.4 sec (range 22-31 sec). The
difference of the PT and APTT times above the reference
mean values was used to calculate PT or APTT prolon-
gation of each group. In addition, serum bilirubin, alka-
line phosphatase, and serum liver transaminases were
drawn at least weekly to assess liver function. The inci-
dence of vitamin K adverse reactions following iv or im
administration was determined by daily patient inter-
views and medical record review. In this study an adverse
reaction was defined as an unexplained report that had
been previously attributed by the manufacturer to vita-
min K iv or im administration. Study data was collected
beginning on the date of the first inclusion of vitamin K
in the TPN solutions (iv group) or on the date of the
first intramuscular injection (im group) and was contin-
ued at daily intervals until TPN was discontinued.
Statistical Analysis
Differences between groups were analyzed using two-
tailed t-tests (age, pretreatment percent ideal body
weight, duration of parenteral nutrition, PT and APTT
prolongation), chi-squared tests (days treated by medical
or surgical services, days of peripheral or central TPN,
PT and APTT outside the normal range), and Fisher’s
exact tests (sex, race, vitamin K side effects).
RESULTS
The safety of vitamin K administration was compared
in the iv and im groups. Efficacy was also determined in
the two groups using PT and APTT times. Efficacy data
from the two groups in the present study was combined
and compared to data from the 1981 study (no vitamin
K).
Treatment Groups
Characteristics of the iv and im groups as well as
similar data from the previous study are shown in Table
I. The iv and im groups were similar in age, sex, pretreat-
TABLE I
Characteristics of the 88 Datients entered into vitamin K studv
X’, t-test, Fisher’s exact test, no significant difference except:
° % days medical us surgical service:
° % days central vs peripheral TPN
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ment percent ideal body weight, and duration of TPN.
The percentage of surgical service patient days was
higher in the im group than in the iv group (p < 0.0001).
Percent days on central ( vs peripheral) TPN was also
higher in the im group (p = 0.05). Because the ordering
of PT and APTT times was controlled by the investiga-
tors, there should not be a service effect. In addition, the
efficacy and safety of intravenous vitamin K administra-
tion has not been observed to be influenced by central
or peripheral routes.
The groups had a similar distribution of underlying
diseases (Table II). During the 8-month study, 24 of a
potential 84 patients who received TPN were excluded.
The reasons for exclusions are listed in Table III. Only
two patients declined to participate in the study; other
exclusions were for not meeting study criteria.
To evaluate differences in TPN populations which
received or did not receive vitamin K, the iv and im
groups were combined then compared to the 1981 no-
vitamin K group. No differences in age, sex, pretreatment
percent ideal body weight, and duration of TPN were
seen. The percentage of surgical TPN days (p = 0.003)
and days on central TPN (p = 0.0001) were higher in
the iv + im group than in the no-vitamin K group.
Ef fectiveness of Vitamin K Administration
PT and APTT times from the iv and im groups were
compared to determine the effectiveness of the two routes
of administration (Table IV). The mean prothrombin
time prolongation of the iv and im group were not sig-
nificantly different. Similarly the percentage of PT times
outside the normal range was not statistically different.
Prolongation of APTT times was similar in the iv and
TABLE II
Underlying diseases of the 88 patients entered into the vitamin K study
TABLE III
Reasons for vitamin K study patient exclusions
im group, although, the iv group had a significantly
higher percentage of APTT times outside the normal
range (p = 0.002).
In this study 17 patients (10 iv, seven im) received
low-dose subcutaneous heparin with TPN. To analyze
the potential impact of heparin on blood clotting tests,
the APTT time prolongation of the heparin group was
compared to that of the nonheparin group. No statistical
difference was seen.
To confirm that regular administration of vitamin K
to patients on TPN was effective in maintaining normal
PT times, the combined iv + im group was compared to
the no-vitamin K group. The mean prolongation of the
no-vitamin K group (3.7 sec) was significantly greater
than that of the vitamin K group (1.9 sec) (p = 0.0004).
Similarly, the no-vitamin K group had a higher percent-
age of PT times outside the normal range (p = 0.002).
Because APTT times were not recorded in the previous
study, comparison between patients in the vitamin K
group and no-vitamin K group was not possible.
Adverse Reactions
The number of adverse reactions reported in the iv
and im groups was similar (Table V). Five side effects
(14.7% of patients) were reported in the iv group and
four (15.4%) in the im group. All reactions were minor
and the patients recovered without sequelae. No study
patient had more than one adverse reaction. The iv group
received 345 solutions containing vitamin K. Forty-eight
intramuscular injections were administered to the im
group.
TABLE IV
Effect of vitamin K on PT and APTT times
X’, t-test, no significant difference except:
a PT prolongation: No-vitamin K > iv + im p = 0.0004.
b PT > 13 sec: no-vitamin K > iv + im X = 9.435, p = 0.002.
’APTT > 31 sec: iv > im X = 9.68, p = 0.002.
TABLE V
Vitamin K side effects
° Percent of patients having side effects.
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DISCUSSION
Effect of iv and im Vitamin K
Since the liver constantly produces coagulation fac-
tors, daily rather than weekly administration of vitamin
K would seem preferrable. This study provides evidence
that iv and im administration of vitamin K given appro-
priately are equally effective in maintaining normal PT
and APTT times. The depot effect of the im injection,
the storage of vitamin K in the liver, the long half-life of
the clotting factors, and the small daily requirement of
vitamin K may all contribute to the apparent equalizing
effect seen in our study. In spite of the pharmacokinetic
differences, our regimens were found to be equally effec-
tive.
Administration guidelines for vitamin K should be
determined by each hospital’s nutrition team. Infusion
with daily TPN solutions would eliminate the additional
discomfort of an intramuscular injection. As demon-
strated, routine administration of vitamin K and blood
coagulation monitoring should decrease the frequency of
elevated PT and APTT times.
Administration of low doses of heparin did not affect
APTT times in either the iv or im group. This supports
earlier observations that mini-dose heparin has a mini-
mal effect on APTT times.&dquo;
Effect of Vitamin K on Prothrombin Time
Regular addition of vitamin K to TPN regimens has
been shown in this study to decrease the incidence of
hypoprothrombinemia. A lower frequency of elevated PT
times was seen in the combined iv + im group when
compared to the no-vitamin K group. Whether the in-
creased incidence of normal clotting times is clinically
significant has not been demonstrated in this study.
However the association between elevated PT times and
the risk of hemorrhagic abnormalities (eg, bleeding,
bruising) has been well documented.5-’ Rational therapy
would seem to include regular vitamin K administration
to patients who are on prolonged TPN therapy.
Adverse Reactions
The frequency of adverse reactions in the iv and im
groups was not statistically different. Three of the five
adverse reactions reported in the iv group (GI bleed,
hematoma, melana) were of more serious nature com-
pared to one of four in the im group (GI bleed). The
reactions encountered were minor, short in duration, and
patients recovered without sequelae. Adverse reactions
were not reproducible with continued vitamin K admin-
istration. In this study 1 mg of iv vitamin K was infused
over at least 8-12 hr. In contrast to clinical reports
mentioned earlier which involved more rapid administra-
tion, episodes of cardiovascular collapse and hypersen-
sitivity reactions were not seen.
The association of serious adverse reactions with in-
travenous or intramuscular vitamin K is not well defined.
Case reports provide useful clinical information but can-
not describe an incidence. One serious adverse reaction
(grand mal seizure) was reported in the Boston Collab-
orative Drug Surveillance of 1238 patients (0.08% inci-
dence). Although no serious adverse reactions were seen
in the 60 study patients, this possibility cannot be ruled
out since the incidence is very low.
The results confirm previous findings that vitamin K
is of value in maintaining normal blood clotting times in
TPN patients. Our study also provides evidence to sup-
port the clinical reports that the intravenous route is a
safe and effective way to administer low doses of vitamin
K over extended periods of time.
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